To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Epoetin-alpha injection effective in reducing need for allogenic blood transfusions

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
April 2013

Epoetin-alpha injection effective in reducing need for allogenic blood transfusions

Vol: 2| Issue: 3| Number:29| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Pre-operative injections of epoetin-alpha versus post-operative retransfusion of autologous shed blood in total hip and knee replacement - prospective randomised clinical trial

J Bone Joint Surg Br. 2008 Aug;90(8):1079-83

Contributing Authors:
AF Moonen BJ Thomassen NT Knoors JJ van Os AD Verburg P Pilot

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

100 patients scheduled to undergo elective total hip or knee replacement, presenting with osteoarthritis were randomized to either receive pre-operative injections of epoetin-alpha (Eprex) or post-operative autologous blood retransfusions using the Bellovac system. These patients exhibited pre-operative haemoglobin levels between 10.0 g/dl and 13.0 g/dl. The results indicated that injections of ep...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue